Literature DB >> 25126158

Signal transductions and nonalcoholic fatty liver: a mini-review.

Lu Zeng1, Wai J Tang1, Jin J Yin1, Bei J Zhou1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, and the incidence increases year by year. The pathogenesis of NAFLD is correlated with insulin resistant (IR), and oxidative stress which induces varied inflammatory cytokines (TNF-α, IL-1, IL-6, etc). Different signal transductions such as MAPK, NF-κB, AMPK, JAK2/STAT3, PPAR, PI3K/Akt, TLR were activated by the pathogenic factors to regulate correlative reactions. Thus, in-depth study of the signal transductions will probably provide new suitable solutions for the prevention and therapy of NAFLD.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; pathogenesis; signal transduction

Year:  2014        PMID: 25126158      PMCID: PMC4132122     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  52 in total

1.  Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.

Authors:  K C Choi; O H Ryu; K W Lee; H Y Kim; J A Seo; S G Kim; N H Kim; D S Choi; S H Baik; K M Choi
Journal:  Biochem Biophys Res Commun       Date:  2005-10-28       Impact factor: 3.575

2.  Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells.

Authors:  Shilla Chakrabarty; Laura Kondratick
Journal:  Cancer Biol Ther       Date:  2006-02-15       Impact factor: 4.742

Review 3.  The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.

Authors:  L Miele; A Forgione; A P Hernandez; M L Gabrieli; V Vero; P Di Rocco; A V Greco; G Gasbarrini; A Gasbarrini; A Grieco
Journal:  Eur Rev Med Pharmacol Sci       Date:  2005 Sep-Oct       Impact factor: 3.507

4.  SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.

Authors:  Motoyuki Kohjima; Nobito Higuchi; Masaki Kato; Kazuhiro Kotoh; Tsuyoshi Yoshimoto; Tatsuya Fujino; Masayoshi Yada; Ryoko Yada; Naohiko Harada; Munechika Enjoji; Ryoichi Takayanagi; Makoto Nakamuta
Journal:  Int J Mol Med       Date:  2008-04       Impact factor: 4.101

5.  Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.

Authors:  Peiyong Zheng; Guang Ji; Zansong Ma; Tao Liu; Lianjun Xin; Hongzhong Wu; Xin Liang; Jianwen Liu
Journal:  Am J Chin Med       Date:  2009       Impact factor: 4.667

Review 6.  AMPK: an emerging drug target for diabetes and the metabolic syndrome.

Authors:  Bei B Zhang; Gaochao Zhou; Cai Li
Journal:  Cell Metab       Date:  2009-05       Impact factor: 27.287

7.  Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1.

Authors:  Hongwei Yuan; John Y-J Shyy; Manuela Martins-Green
Journal:  J Hepatol       Date:  2009-05-18       Impact factor: 25.083

8.  Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease.

Authors:  Yuan Liu; Xiaofeng Han; Zhaolian Bian; Yanshen Peng; Zhengrui You; Qixia Wang; Xiaoyu Chen; Dekai Qiu; Xiong Ma
Journal:  Dig Dis Sci       Date:  2011-09-23       Impact factor: 3.199

9.  Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.

Authors:  Satoru Matsuda; Mayumi Kobayashi; Yasuko Kitagishi
Journal:  ISRN Endocrinol       Date:  2013-01-30

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  26 in total

1.  Relationship of adiponectin to markers of oxidative stress in type 2 diabetic patients: influence of incipient diabetes-associated kidney disease.

Authors:  Cosmina Ioana Bondor; Alina Ramona Potra; Diana Moldovan; Crina Claudia Rusu; Mariana Ciorba Pop; Adriana Muresan; Dan Stefan Vladutiu; Ina Maria Kacso
Journal:  Int Urol Nephrol       Date:  2015-05-14       Impact factor: 2.370

2.  [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].

Authors:  Xiao-Rui Yao; Fan Xia; Wai-Jiao Tang; Ben-Jie Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

3.  Effect of combined application insulin and insulin detemir on continous glucose monitor in children with type 1 diabetes mellitus.

Authors:  Xiao-Yun Chen; Qing Dong; Gui-Mei Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  miR-122-5p/KIF5B/AMPK/AKT regulatory network regulates the progression of NAFLD.

Authors:  Jianling Zhang; Huanjun Huang
Journal:  Am J Transl Res       Date:  2021-02-15       Impact factor: 4.060

5.  Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease.

Authors:  Nikhil Y Patil; Iulia Rus; Emma Downing; Ashok Mandala; Jacob E Friedman; Aditya D Joshi
Journal:  J Pharmacol Exp Ther       Date:  2022-08-06       Impact factor: 4.402

6.  Nootkatone, a Sesquiterpene Ketone From Alpiniae oxyphyllae Fructus, Ameliorates Metabolic-Associated Fatty Liver by Regulating AMPK and MAPK Signaling.

Authors:  Zhang Yong; Huang Zibao; Zhou Zhi; Ma Ning; Wang Ruiqi; Chen Mimi; He Xiaowen; Dong Lin; Xia Zhixuan; Liu Qiang; Lu Weiying; Zhang Xiaopo
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

Review 7.  Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.

Authors:  Adnan Malik; Mahum Nadeem; Muhammad Imran Malik
Journal:  Clin J Gastroenterol       Date:  2021-08-09

8.  MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis.

Authors:  Timea Csak; Shashi Bala; Dora Lippai; Karen Kodys; Donna Catalano; Arvin Iracheta-Vellve; Gyongyi Szabo
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

9.  Effects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside.

Authors:  Carla Sá; Ana Rita Oliveira; Cátia Machado; Marisa Azevedo; Cristina Pereira-Wilson
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-31       Impact factor: 2.629

10.  Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer.

Authors:  Consolato M Sergi
Journal:  Diagnostics (Basel)       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.